Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
월요일, 9월 07

Edwards Lifesciences Corp

EWNYSE
Trade with Public
Trade with Public
$89.90
0.120.13%
가까이에: Sep 4, 5:00 PM EST
$89.90
N/A
시간외: Sep 4, 4:15 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Edwards Lifesciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Edwards Lifesciences (EW).

Price Target Range — 8 Quarters

Analyst Consensus — 20 Analysts

17Buy
3Hold
Consensus RatingBuy# Analysts20Avg. Consensus PT$100Upside to Avg. PT+11.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jul 28, 2026UBSPatrick WoodAssumesNeutral→Buy$110
Jul 24, 2026Leerink PartnersMike KratkyUpgradeMarket Perform→Outperform$87→$101
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Edwards Lifesciences, Raises Price Target to $105

JP Morgan analyst Robbie Marcus maintains Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $100 to $105.
Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on Edwards Lifesciences, Raises Price Target to $101

Piper Sandler analyst Adam Maeder reiterates Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $100 to $101.
Benzinga Newsdesk

Edwards Earnings Add Fuel To Bullish MedTech Thesis, Analyst Says

Edwards Lifesciences tops Q2 Wall Street estimates with $1.74B in revenue. EW stock jumps as analysts see continued upside ahead.
Vandana Singh

PRO
Truist Securities Maintains Hold on Edwards Lifesciences, Raises Price Target to $95

Truist Securities analyst Richard Newitter maintains Edwards Lifesciences (NYSE:EW) with a Hold and raises the price target from $90 to $95.
Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Edwards Lifesciences, Raises Price Target to $105

Mizuho analyst Anthony Petrone maintains Edwards Lifesciences (NYSE:EW) with a Outperform and raises the price target from $100 to $105.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Edwards Lifesciences, Raises Price Target to $110

RBC Capital analyst Shagun Singh maintains Edwards Lifesciences (NYSE:EW) with a Outperform and raises the price target from $100 to $110.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved